Kohout Trudy A, Nicholas Shelby L, Perry Stephen J, Reinhart Greg, Junger Sachiko, Struthers R Scott
Department of Exploratory Discovery, Neurocrine Biosciences Inc., San Diego, California 92121, USA.
J Biol Chem. 2004 May 28;279(22):23214-22. doi: 10.1074/jbc.M402125200. Epub 2004 Mar 30.
Many members of the chemokine receptor family of G protein-coupled receptors utilize multiple endogenous ligands. However, differences between the signaling properties of multiple chemokines through a single receptor have yet to be well characterized. In this study we investigated the early signaling events of CCR7 initiated by its two endogenous ligands, CCL19 and CCL21. Both CCL19 and CCL21 induce G protein activation and calcium mobilization with equal potency. However, only activation by CCL19, not CCL21, promotes robust desensitization of endogenous CCR7 in the human T cell lymphoma cell line H9. Desensitization occurs through the induction of receptor phosphorylation and beta-arrestin recruitment (shown in HEK293 cells expressing CCR7-FLAG). The sites of CCL19-induced phosphorylation were mapped by mutating to alanines the serines and threonines found within kinase phosphorylation consensus sequences in the carboxyl terminus of CCR7. A cluster of sites, including Thr-373-376 and Ser-378 is important for CCL19-mediated phosphorylation of the receptor, whereas residues serine 356, 357, 364, and 365 are important for basal receptor phosphorylation by protein kinase C. Activation of CCR7 by both ligands leads to signaling to the ERK1/2 mitogen-activated protein kinase pathway. However, CCL19 promotes 4-fold more ERK1/2 phosphorylation than does CCL21. The mechanism by which CCL19 activates ERK1/2 was determined to be beta-arrestin-dependent, because it is reduced both by depletion of beta-arrestin-2 with small interfering RNA and by elimination of the phosphorylation sites in the tail of the receptor. Taken together, these findings demonstrate that CCL19 and CCL21 place CCR7 in functionally distinct conformations that are independent of their G protein-coupling potency: one that allows the efficient desensitization of the receptor and activation of ERK1/2, and another that is impaired in these functions.
G蛋白偶联受体的趋化因子受体家族的许多成员利用多种内源性配体。然而,多种趋化因子通过单一受体的信号传导特性之间的差异尚未得到充分表征。在本研究中,我们研究了CCR7由其两种内源性配体CCL19和CCL21引发的早期信号事件。CCL19和CCL21均以相同效力诱导G蛋白激活和钙动员。然而,只有CCL19激活,而非CCL21,能促进人T细胞淋巴瘤细胞系H9中内源性CCR7的强烈脱敏。脱敏通过受体磷酸化的诱导和β-抑制蛋白募集而发生(在表达CCR7-FLAG的HEK293细胞中显示)。通过将CCR7羧基末端激酶磷酸化共有序列中发现的丝氨酸和苏氨酸突变为丙氨酸,绘制了CCL19诱导的磷酸化位点。包括Thr-373-376和Ser-378在内的一组位点对于CCL19介导的受体磷酸化很重要,而丝氨酸356、357、364和365残基对于蛋白激酶C介导的基础受体磷酸化很重要。两种配体激活CCR7均导致向ERK1/2丝裂原活化蛋白激酶途径的信号传导。然而,CCL19促进的ERK1/2磷酸化比CCL21多4倍。已确定CCL19激活ERK1/2的机制是β-抑制蛋白依赖性的,因为它通过小干扰RNA耗尽β-抑制蛋白-2以及消除受体尾部的磷酸化位点而降低。综上所述,这些发现表明CCL19和CCL21使CCR7处于功能上不同的构象,这些构象与其G蛋白偶联效力无关:一种允许受体有效脱敏和ERK1/2激活,另一种在这些功能上受损。